pixel

Vivos Therapeutics and Candid Announce Strategic Collaboration to Deliver A Comprehensive Sleep Apnea and Orthodontic Treatment Solution

News

HIGHLANDS RANCH
Colorado, October 18, 2021

Vivos Therapeutics, Inc. (the “Company” or “Vivos”) (NASDAQ:VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from mild to moderate obstructive sleep apnea (OSA) and snoring, and Candid Care Co. (“Candid”), a digital platform for oral healthcare, today announced a new collaboration that will seek to provide patients with a comprehensive, whole-mouth solution to diagnose and treat OSA in adult patients and provide orthodontic treatment from the same provider network.

At the core of this collaboration, Vivos and Candid will market each company’s products and areas of expertise to deliver a comprehensive sleep and oral health solution to patients in the United States and Canada. The focus of the collaboration will be Candid’s CandidPro clear aligner for straightening teeth and the Vivos System for treating OSA. The two companies will also share educational resources, training, and key opinion leaders to bridge the gap between airway health and orthodontic therapy.

“By teaming with Candid, we are aiming to provide patients with access not only to our highly effective Vivos System, but also simultaneous access to CandidPro’s novel orthodontic treatment. We believe the Vivos-Candid collaboration will provide for the first solution that seamlessly integrates sleep and orthodontic therapy to create better patient outcomes for treating OSA and enhance overall health and wellness across the board.” said Kirk Huntsman, Vivos Chairman and CEO. “We are hopeful that this joint effort will increase market penetration and accelerate revenue growth for both companies as we each attract and expand our respective North American dental and healthcare networks.”

Additionally, under the terms of the agreement, Vivos and Candid will join forces to explore new research and development opportunities for device development and other alliances related to orthodontics, OSA, and snoring. Candid will also conduct specialized training sessions at the Vivos Institute, the Company’s new state-of-the-art international training center in Denver, Colorado, as well as semi-annual seminars for both dentists and medical doctors to provide additional learning opportunities. The parties will act on a non-exclusive basis, although during the term of the agreement, Candid’s aligners will become the official clear aligner of Vivos and Vivos’ oral devices and proprietary protocols will become the official sleep therapy program of Candid.

“Candid was built on a foundation of clinical excellence and has always put patient health first. Since launching Candid in 2017, my co-founders and I have strived to shine a light on the correlation between teeth alignment, oral health, and chronic illnesses, like obstructive sleep apnea. Vivos Therapeutics and Candid are where airway and sleep, oral health, and orthodontic therapy come together for the first time,” added Nick Greenfield, Candid Co-Founder and CEO. “By combining Vivos’ therapeutic protocol for OSA and its VIP doctor network with Candid’s treatment methodology and CandidPro network, together we look forward to offering a full-service solution for patients suffering from OSA.”

“As someone who focuses his practice on combining sleep-disordered breathing, orthodontics and comprehensive dentistry, I know how important it is to treat all oral health conditions as part of one comprehensive solution,” concluded Dr. Ben Miraglia, DDS, Chief Clinical Consultant of Airway Health Solutions, Vivos Provider and recognized thought leader in sleep-disordered breathing, clear aligner therapy and craniofacial development. “The Vivos-Candid alliance is a true win-win for patients who are looking to improve their sleep, oral health and confidence all at the same time.”

Cautionary Note Regarding Forward-Looking Statements

This press release and statements of the Company’s management made in connection therewith contain “forward-looking statements” (as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended) concerning future events, particularly with respect to the public offering described herein. Words such as “aim,” “may,” “could,” “expects,” “projects,” “intends,” “plans,” “believes,” “predicts,” “anticipates,” “hopes,” “estimates” and variations of such words and similar expressions are intended to identify forward-looking statements. These statements involve known and unknown risks and are based upon several assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond Vivos’ control. Actual results (including, without limitation, the anticipated benefits of Australian regulatory approval described here on the Company’s sales and ability to obtain regulatory approvals in other countries) may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, the risk factors described in Vivos’ filings with the Securities and Exchange Commission (“SEC”). Vivos’ filings can be obtained free of charge on the SEC’s website at sec.gov. Except to the extent required by law, Vivos expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Vivos’ expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.

Vivos Investor Relations Contact:

Julie Gannon
Investor Relations Officer
720-442-8113
[email protected]

Vivos Media Relations Contact:

Amy Cook
Public Relations Officer
949-813-0182
[email protected]